This disclosure relates generally to medical treatment systems and, more particularly, but not by way of limitation, to micro-porous conduits, dressings, and systems suitable for use in treating a tissue site.
Depending on the medical circumstances, reduced pressure may be used for, among other things, reduced-pressure therapy to encourage granulation at a tissue site, draining fluids at a tissue site, closing a wound, reducing edema, promoting perfusion, and fluid management. Common conduits, dressings, and systems may be susceptible blockages that can cause a reduction in the effectiveness of the therapy or a complete loss of therapy. Such a situation can occur, for example, if the amount of fluid in the system exceeds the fluid capacity of the system. Blockages in conduits, for example, may prevent reduced pressure from reaching the tissue site and/or prevent accurate measurement of the reduced pressure at the tissue site for reduced pressure control. Thus, improvements to conduits, dressings, and systems that may enhance reliability are desirable.
Shortcomings with certain aspects of tissue treatment dressings, systems, and methods are addressed as shown and described in a variety of illustrative, non-limiting embodiments herein.
In some embodiments, provided is a system for treating a tissue site that may include a manifold, a sealing drape, a porous conduit, and a therapy device. The manifold may be adapted to be positioned proximate the tissue site. The sealing drape may be adapted to cover the manifold and the tissue site to provide a sealed space between the sealing drape and the tissue site. The porous conduit may be adapted to be in fluid communication with the manifold and the sealed space. The porous conduit may include a central lumen, a first porous wall, a barrier layer, and a second porous wall. The first porous wall may be positioned substantially concentric about the central lumen. The first porous wall may have an open porous structure defining a plurality of interconnected pores in fluid communication with one another. The barrier layer may be positioned substantially concentric about the first porous wall. The barrier layer may be comprised of a non-porous material. The second porous wall may be positioned substantially concentric about the barrier layer. The second porous wall may have an open porous structure defining a plurality of interconnected pores in fluid communication with one another. The barrier layer may substantially preclude fluid communication laterally between the first porous wall and the second porous wall. The therapy device may be adapted to be in fluid communication with the porous conduit.
In other embodiments, provided is a system for treating a tissue site that may include a manifold, a sealing drape, a porous conduit, and a therapy device. The manifold may be adapted to be positioned proximate the tissue site. The sealing drape may be adapted to cover the manifold and the tissue site to provide a sealed space between the sealing drape and the tissue site. The porous conduit may be adapted to be disposed in the sealed space in fluid communication with the manifold and the sealed space. The porous conduit may include a central lumen and a porous wall. The porous wall may be positioned substantially concentric about the central lumen. The porous wall may have an open porous structure defining a plurality of interconnected pores in fluid communication with one another. The therapy device may be adapted to be in fluid communication with the porous conduit. The therapy device may include a reduced-pressure source and a pressure sensor. The reduced-pressure source may be adapted to be in fluid communication with the central lumen, and the pressure sensor may be adapted to be in fluid communication with the porous wall.
In other embodiments, provided is a system for treating a tissue site that may include a manifold, a sealing drape, a porous conduit, and a therapy device. The manifold may be adapted to be positioned proximate the tissue site and to distribute reduced pressure to the tissue site. The sealing drape may be adapted to cover the manifold and the tissue site to provide a sealed space between the sealing drape and the tissue site. The porous conduit may be adapted to be disposed in the sealed space in fluid communication with the manifold and the sealed space. The porous conduit may include a central lumen, a first porous wall, a barrier layer, and a second porous wall. The first porous wall may be positioned substantially concentric about the central lumen. The first porous wall may have an open porous structure defining a plurality of interconnected pores in fluid communication with one another. The first porous wall may be comprised of bonded particles defining the interconnected pores. The bonded particles may be sintered polymer particles. The barrier layer may be positioned substantially concentric about the first porous wall. The barrier layer may be comprised of a non-porous, liquid impermeable material. The second porous wall may be positioned substantially concentric about the barrier layer. The second porous wall may have an open porous structure defining a plurality of interconnected pores in fluid communication with one another. The second porous wall may be comprised of bonded particles defining the interconnected pores. The bonded particles may be sintered polymer particles. The barrier layer may substantially preclude fluid communication laterally between the first porous wall and the second porous wall. The therapy device may be adapted to be in fluid communication with the porous conduit. The therapy device may include a reduced-pressure source, a fluid instillation source, and a pressure sensor. The reduced-pressure source may be in fluid communication with the central lumen, the fluid instillation source may be in fluid communication with the first porous wall, and the pressure sensor may be in fluid communication with the second porous wall.
Other aspects, features, and advantages of the illustrative embodiments will become apparent with reference to the drawings and detailed description that follow.
A more complete understanding of this specification may be obtained by reference to the following detailed description when taken in conjunction with the accompanying drawings wherein:
In the following detailed description of the non-limiting, illustrative embodiments, reference is made to the accompanying drawings that form a part hereof. Other embodiments may be utilized, and logical, structural, mechanical, electrical, and chemical changes may be made without departing from the scope of this specification. To avoid detail not necessary to enable those skilled in the art to practice the embodiments described herein, the description may omit certain information known to those skilled in the art. The following detailed description is provided without limitation and with the scope of the illustrative embodiments being defined by the appended claims.
Referring to the drawings, provided is a system 100 for treating a tissue site 104 that may be suitable for use with reduced pressure. The tissue site 104 may extend through or otherwise involve an epidermis 106, a dermis 108, and a subcutaneous tissue 110. The tissue site 104 may be a sub-surface tissue site as depicted in
Further, the tissue site 104 may be the bodily tissue of any human, animal, or other organism, including bone tissue, adipose tissue, muscle tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, ligaments, or any other tissue. Treatment of the tissue site 104 may include removal of fluids, e.g., exudate or ascites. As described below, components of the system 100 may be fluidly coupled to each other to provide a path for transferring fluids (e.g., liquid and/or gas) between the components. As used herein, unless otherwise indicated, “or” does not require mutual exclusivity.
Referring to
The manifold 128 may be a substance or structure capable of applying reduced pressure to, delivering fluids to, or removing fluids from the tissue site 104. In some embodiments, the manifold 128 may be used to distribute fluids such as medications, antibacterials, growth factors, and various solutions to the tissue site 104. For example, the manifold 128 may be a porous and permeable foam or foam-like material including a plurality of flow channels or pathways that distribute fluids to and remove fluids from the tissue site 104. The manifold 128 may include, without limitation, devices that have structural elements arranged to form flow channels, such as, cellular foam, open-cell foam, porous tissue collections, liquids, gels, and foams that include, or cure to include, flow channels. Additionally, the manifold 128 may be a gauze, felted mat, or any other material suited to a particular biological application.
In some embodiments, the manifold 128 may be a porous, hydrophobic material such as a polyurethane, open-cell reticulated foam manufactured under the trade name GranuFoam® by Kinetic Concepts, Inc. of San Antonio, Texas Other layers may be included in or on the manifold 128, such as absorptive materials, wicking materials, hydrophobic materials, and hydrophilic materials.
The sealing drape 132 may be adapted to cover the second side 136 of the manifold 128 and to seal to a peripheral surface 138 proximate the tissue site 104. The peripheral surface 138 may be undamaged epidermis 106 peripheral to the tissue site 104. In this manner, the sealing drape 132 may provide a fluid seal between the sealing drape 132 and the tissue site 104 with the second side 136 of the manifold 128 facing the sealing drape 132. In some embodiments, the manifold 128 may be positioned between the tissue site 104 and the sealing drape 132. The fluid seal provided by the sealing drape 132 may be a seal adequate to hold reduced pressure at a desired tissue site given the particular reduced-pressure source involved. Thus, the sealing drape 132 may provide a sealed space 140 proximate to the tissue site 104 that may be substantially isolated from the external environment and capable of maintaining reduced pressure.
The sealing drape 132 may comprise any material suitable for providing the fluid seal described above. For example, the sealing drape 132 may comprise one or more of the following materials: hydrophilic polyurethane; cellulosics; hydrophilic polyamides; polyvinyl alcohol; polyvinyl pyrrolidone; hydrophilic acrylics; hydrophilic silicone elastomers; an INSPIRE 2301 material from Expopack Advanced Coatings of Wrexham, United Kingdom; a thin, uncoated polymer drape; natural rubbers; polyisoprene; styrene butadiene rubber; chloroprene rubber; polybutadiene; nitrile rubber; butyl rubber; ethylene propylene rubber; ethylene propylene diene monomer; chlorosulfonated polyethylene; polysulfide rubber; polyurethane (PU); EVA film; co-polyester; silicones; a silicone drape; a 3M Tegaderm® drape; a polyurethane (PU) drape such as one available from Avery Dennison Corporation of Pasadena, California; polyether block polyamide copolymer (PEBAX), for example, from Arkema, France; or other appropriate material. Further, the sealing drape 132 may be a hybrid drape formed of a combination of the previously described materials.
In some embodiments, the sealing drape 132 may be comprised of a liquid impermeable material that may allow vapor and inhibit liquids from exiting the sealed space 140 of the dressing 116. The sealing drape 132 may be a flexible, breathable film having a high Moisture Vapor Transfer Rate (MVTR) of, for example, at least about 300 g/m2 per 24 hours. The sealing drape 132 may comprise a range of medically approved films having a thickness between about 15 microns (μm) to about 50 microns (μm). In other embodiments, a low or no vapor transfer drape might be used.
In some embodiments, the dressing 116 may also include additional layers (not shown) that may be positioned between the tissue site 104 and the sealing drape 132. For example, the dressing 132 may include an absorption layer, a tissue-interface layer, or additional manifold layers. The dressing 116 may also include an attachment device (not shown) capable of adhering or otherwise sealing the sealing drape 132 to the peripheral surface 138. The attachment device may include, for example, silicones and hot-melt adhesives. Other suitable attachment devices may include, for example, hydrogels and hydrocolloids.
Continuing with the embodiments of
The first porous wall 152 may be positioned substantially concentric about the central lumen 148 and in fluid communication with the central lumen 148. Further, the first porous wall 152 and the central lumen 148 may each be in fluid communication with the manifold 128 and the sealed space 140. For example, the first porous wall 152 may have an open porous structure defining a plurality of interconnected pores 164, shown in
The barrier layer 156 may be positioned substantially concentric about the first porous wall 152. The barrier layer 156 may be, for example, comprised of a material that is liquid impermeable and/or non-porous. The material comprising the barrier layer 156 may also be a hydrophobic material. The barrier layer 156 may be applied as part of the porous conduit 120, for example, through a co-extrusion process or during molding. In some embodiments, an internal barrier layer (not shown) may be disposed adjacent the first porous wall 152 within the central lumen 148. The internal barrier layer may be comprised of a similar material described above for the barrier layer 156.
The second porous wall 160 may be positioned substantially concentric about the barrier layer 156. Similar to the first porous wall 152, the second porous wall 160 may have an open porous structure defining a plurality of interconnected pores 172, shown in
Continuing with
In other embodiments (not shown), additional lumens (not shown) may be integrated into the porous conduit 120 as necessary to suit a particular application. For example, the central lumen 148 may be divided into two or more smaller lumens that may be positioned in a substantially flat configuration beside one another. Such a configuration may enhance patient comfort by providing a low profile for the porous conduit 120 and the system 100 that may be less likely to snag on clothing and other obstacles.
The therapy device 124 and the porous conduit 120 may be adapted to be in fluid communication with one another. As shown in
The reduced-pressure source 188 may provide reduced pressure as a part of the system 100. The reduced-pressure source 188 may be any device for supplying a reduced pressure, such as a vacuum pump, wall suction, micro-pump, or other source. As shown in
The term reduced pressure may refer to a pressure less than the ambient pressure at the tissue site being subjected to treatment. The reduced pressure may be less than the atmospheric pressure, and less than a hydrostatic pressure at a tissue site. Unless otherwise indicated, values of pressure stated herein are gauge pressures. Consistent with the use herein, an increase in reduced pressure or vacuum pressure may refer to a relative reduction in absolute pressure.
As shown in
Further, as shown in
In some embodiments, the porous conduit 120 may have a variety of shapes and geometries to suit a particular application. For example, geometries such as ovals, rectangles, and polygons may be utilized for the cross-sectional shape of the porous conduit 120. As shown in
In other embodiments, the porous conduit 120 may have any number of porous walls, analogous to the first and the second porous walls 152, 160, to suit a particular application. Likewise, barrier layers in the porous conduit 120 that may be analogous to the barrier layer 156 and the external barrier layer 182 may be added or omitted as necessary. For example,
Referring generally to
Continuing with
The conduit interface 495 may include a reduced-pressure lumen 448a that may be in fluid communication between the central lumen 148 and the reduced-pressure source 188. Further, the conduit interface 495 may include a fluid instillation lumen 452a that may be in fluid communication between the first porous wall 152 and the fluid instillation source 190. Additionally, the conduit interface 495 may include a sensing lumen 460a that may be in fluid communication between the second porous wall 160 and the pressure sensor 192. The conduit interface 495 may include any number of lumens as appropriate for providing fluid communication among embodiments of the porous conduit, the multiple lumen conduit, and the therapy device according to this disclosure.
The multiple lumen conduit 497 may be adapted to be coupled in fluid communication between the conduit interface 495 and the therapy device 124. Analogous to the conduit interface 495, the multiple lumen conduit 497 may include a reduced-pressure lumen 448b that may be in fluid communication between the central lumen 148 and the reduced-pressure source 188. Further, the multiple lumen conduit 497 may include a fluid instillation lumen 452b that may be in fluid communication between the first porous wall 152 and the fluid instillation source 190. Additionally, the multiple lumen conduit 497 may include a sensing lumen 460b that may be in fluid communication between the second porous wall 160 and the pressure sensor 192. The reduced-pressure lumen 448b, the fluid instillation lumen 452b, and the sensing lumen 460b of the multiple lumen conduit 497 may be in fluid communication with the reduced-pressure lumen 448a, the fluid instillation lumen 452a, and the sensing lumen 460a of the conduit interface 495, respectively. The multiple lumen conduit 497 may include any number of lumens as appropriate for providing fluid communication among embodiments of the porous conduit, the conduit interface, and the therapy device according to this disclosure.
In operation, the system 100 may be applied to a patient in the operating room after a surgical procedure or elsewhere. According to one illustrative embodiment, the manifold 128 may be placed proximate to the tissue site 104. The manifold 128 may be placed within the tissue site 104, or may overlay a portion of the tissue site 104. The sealing drape 132 may be placed over the manifold 128 such that a portion of the sealing drape 132 overlays the peripheral surface 138 around the tissue site 104. The sealing drape 132 may be secured to the peripheral surface 138 in order to form the sealed space 140 between the tissue site 104 and the sealing drape 132 described above. The fluid seal forming the sealed space 140 need only be adequate to allow the system 100 to maintain a reduced pressure at the tissue site 104 for a desired treatment time. The individual components of the dressing 116 may be sized according to the particular application or the procedure being performed by a healthcare provider. For example, the components of the dressing 116 may be sized, shaped, and configured to work in different anatomical applications such as the abdomen, chest, thighs, hip, etc.
The porous conduit 120 may be fed through the aperture 184 in the sealing drape 132 and pushed into the manifold 128, or fed between the manifold 128 and the tissue site 104. To assist with the application of the system 100, the manifold 128 may be pre-cut with holes (not shown) sized to receive the porous conduit 120. In some embodiments, the porous conduit 120 may be routed around the tissue site 104 and the manifold 128 may be subsequently applied allowing for a portion of the porous conduit 120 to be positioned proximate the aperture 184 to facilitate connection with the therapy device 124.
As described above, the porous conduit 120 may be coupled in fluid communication to the therapy device 124 utilizing, for example, the external end 180 of the porous conduit 120, or the conduit interface 495 and the multiple lumen conduit 497. The reduced-pressure source 188 may then be activated to deliver reduced pressure to the sealed space 140.
Upon application of the reduced pressure to the dressing 116 through the porous conduit 120, fluids from the tissue site 104 may be drawn into the manifold 128 and the porous conduit 120. In some embodiments, the system 100 may include a fluid canister (not shown) positioned in fluid communication between the central lumen 148 in the porous conduit 120 and the reduced-pressure source 188 in the therapy device 124 for capturing excess fluids. As fluids from the tissue site 104 enter the central lumen 148, the fluids may cause blockages by, for example, gelling or otherwise thickening within the central lumen 148. The interconnected pores 164 in the first porous wall 152 may provide a plurality of alternate fluid communication passageways that may be resistant to such blockages. Further, should a blockage occur in the first porous wall 152, the interconnected pores 164 and corresponding passageways may be sufficiently numerous to maintain fluid communication with the sealed space 140. In this manner, reduced pressure therapy may be reliably maintained with the tissue site 104. Further, instillation fluids from the instillation fluid source 190 that may be in fluid communication with the first porous wall 152 may travel reliability through the interconnected pores 164 to the tissue site 104. Similar to the interconnected pores 164 of the first porous wall 152, the interconnected pores 172 of the second porous wall 160 may provide a plurality of alternate fluid communication passageways that may be numerous and resistant to blockages. In this manner, the pressure sensor 192 that may be in fluid communication with the second porous wall 160 may provide an accurate pressure signal corresponding to the reduced pressure in the sealed space 140 of the dressing 116 for reliably controlling the reduced pressure. Further, the external surface area 142 of the insertion end 178 of the porous conduit 120 being disposed in the sealed space 140 and in fluid communication between the sealed space 140 and the pressure sensor 192 may enhance the reliability of the pressure signal generated by the pressure sensor 192.
Although this specification discloses advantages in the context of certain illustrative, non-limiting embodiments, various changes, substitutions, permutations, and alterations may be made without departing from the scope of the specification as defined by the appended claims. Further, any feature described in connection with any one embodiment may also be applicable to any other embodiment.
This application is a continuation of U.S. patent application Ser. No. 15/709,154, filed Sep. 19, 2017, which is a continuation of U.S. patent application Ser. No. 14/173,947, now U.S. Pat. No. 9,795,515, filed Feb. 6, 2014, which claims the benefit, under 35 USC § 119(e), of the filing of U.S. Provisional Patent Application No. 61/782,713, entitled “MICRO-POROUS CONDUIT,” filed Mar. 14, 2013, each of which is incorporated herein in its entirety by reference for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
1355846 | Rannells | Oct 1920 | A |
2547758 | Keeling | Apr 1951 | A |
2632443 | Lesher | Mar 1953 | A |
2682873 | Evans et al. | Jul 1954 | A |
2910763 | Lauterbach | Nov 1959 | A |
2969057 | Simmons | Jan 1961 | A |
3066672 | Crosby, Jr. et al. | Dec 1962 | A |
3367332 | Groves | Feb 1968 | A |
3520300 | Flower, Jr. | Jul 1970 | A |
3568675 | Harvey | Mar 1971 | A |
3648692 | Wheeler | Mar 1972 | A |
3682180 | McFarlane | Aug 1972 | A |
3826254 | Mellor | Jul 1974 | A |
4080970 | Miller | Mar 1978 | A |
4096853 | Weigand | Jun 1978 | A |
4139004 | Gonzalez, Jr. | Feb 1979 | A |
4165748 | Johnson | Aug 1979 | A |
4184510 | Murry et al. | Jan 1980 | A |
4233969 | Lock et al. | Nov 1980 | A |
4245630 | Lloyd et al. | Jan 1981 | A |
4256109 | Nichols | Mar 1981 | A |
4261363 | Russo | Apr 1981 | A |
4275721 | Olson | Jun 1981 | A |
4284079 | Adair | Aug 1981 | A |
4297995 | Golub | Nov 1981 | A |
4333468 | Geist | Jun 1982 | A |
4373519 | Errede et al. | Feb 1983 | A |
4382441 | Svedman | May 1983 | A |
4392853 | Muto | Jul 1983 | A |
4392858 | George et al. | Jul 1983 | A |
4419097 | Rowland | Dec 1983 | A |
4465485 | Kashmer et al. | Aug 1984 | A |
4475909 | Eisenberg | Oct 1984 | A |
4480638 | Schmid | Nov 1984 | A |
4525166 | Leclerc | Jun 1985 | A |
4525374 | Vaillancourt | Jun 1985 | A |
4540412 | Van Overloop | Sep 1985 | A |
4543100 | Brodsky | Sep 1985 | A |
4548202 | Duncan | Oct 1985 | A |
4551139 | Plaas et al. | Nov 1985 | A |
4569348 | Hasslinger | Feb 1986 | A |
4605399 | Weston et al. | Aug 1986 | A |
4608041 | Nielsen | Aug 1986 | A |
4640688 | Hauser | Feb 1987 | A |
4655754 | Richmond et al. | Apr 1987 | A |
4664662 | Webster | May 1987 | A |
4710165 | McNeil et al. | Dec 1987 | A |
4733659 | Edenbaum et al. | Mar 1988 | A |
4743232 | Kruger | May 1988 | A |
4758220 | Sundblom et al. | Jul 1988 | A |
4787888 | Fox | Nov 1988 | A |
4826494 | Richmond et al. | May 1989 | A |
4838883 | Matsuura | Jun 1989 | A |
4840187 | Brazier | Jun 1989 | A |
4863449 | Therriault et al. | Sep 1989 | A |
4872450 | Austad | Oct 1989 | A |
4878901 | Sachse | Nov 1989 | A |
4897081 | Poirier et al. | Jan 1990 | A |
4906233 | Moriuchi et al. | Mar 1990 | A |
4906240 | Reed et al. | Mar 1990 | A |
4919654 | Kalt | Apr 1990 | A |
4941882 | Ward et al. | Jul 1990 | A |
4953565 | Tachibana et al. | Sep 1990 | A |
4969880 | Zamierowski | Nov 1990 | A |
4985019 | Michelson | Jan 1991 | A |
5037397 | Kalt et al. | Aug 1991 | A |
5086170 | Luheshi et al. | Feb 1992 | A |
5092858 | Benson et al. | Mar 1992 | A |
5100396 | Zamierowski | Mar 1992 | A |
5134994 | Say | Aug 1992 | A |
5149331 | Ferdman et al. | Sep 1992 | A |
5167613 | Karami et al. | Dec 1992 | A |
5176663 | Svedman et al. | Jan 1993 | A |
5215522 | Page et al. | Jun 1993 | A |
5232453 | Plass et al. | Aug 1993 | A |
5261893 | Zamierowski | Nov 1993 | A |
5278100 | Doan et al. | Jan 1994 | A |
5279550 | Habib et al. | Jan 1994 | A |
5298015 | Komatsuzaki et al. | Mar 1994 | A |
5342376 | Ruff | Aug 1994 | A |
5344415 | DeBusk et al. | Sep 1994 | A |
5358494 | Svedman | Oct 1994 | A |
5437622 | Carion | Aug 1995 | A |
5437651 | Todd et al. | Aug 1995 | A |
5527293 | Zamierowski | Jun 1996 | A |
5549584 | Gross | Aug 1996 | A |
5556375 | Ewall | Sep 1996 | A |
5607388 | Ewall | Mar 1997 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5645081 | Argenta et al. | Jul 1997 | A |
6071267 | Zamierowski | Jun 2000 | A |
6135116 | Vogel et al. | Oct 2000 | A |
6241747 | Ruff | Jun 2001 | B1 |
6287316 | Agarwal et al. | Sep 2001 | B1 |
6345623 | Heaton et al. | Feb 2002 | B1 |
6488643 | Tumey et al. | Dec 2002 | B1 |
6493568 | Bell et al. | Dec 2002 | B1 |
6553998 | Heaton et al. | Apr 2003 | B2 |
6814079 | Heaton et al. | Nov 2004 | B2 |
7846141 | Weston | Dec 2010 | B2 |
8062273 | Weston | Nov 2011 | B2 |
8216198 | Heagle et al. | Jul 2012 | B2 |
8251979 | Malhi | Aug 2012 | B2 |
8257327 | Blott et al. | Sep 2012 | B2 |
8398614 | Blott et al. | Mar 2013 | B2 |
8449509 | Weston | May 2013 | B2 |
8529548 | Blott et al. | Sep 2013 | B2 |
8535296 | Blott et al. | Sep 2013 | B2 |
8551060 | Schuessler et al. | Oct 2013 | B2 |
8568386 | Malhi | Oct 2013 | B2 |
8679081 | Heagle et al. | Mar 2014 | B2 |
8834451 | Blott et al. | Sep 2014 | B2 |
8926592 | Blott et al. | Jan 2015 | B2 |
9017302 | Vitaris et al. | Apr 2015 | B2 |
9198801 | Weston | Dec 2015 | B2 |
9211365 | Weston | Dec 2015 | B2 |
9289542 | Blott et al. | Mar 2016 | B2 |
9795515 | Robinson | Oct 2017 | B2 |
20020077661 | Saadat | Jun 2002 | A1 |
20020115951 | Norstrem et al. | Aug 2002 | A1 |
20020120185 | Johnson | Aug 2002 | A1 |
20020143286 | Tumey | Oct 2002 | A1 |
20050137539 | Biggie | Jun 2005 | A1 |
20130123723 | Tout | May 2013 | A1 |
20140163491 | Schuessler et al. | Jun 2014 | A1 |
20150080788 | Blott et al. | Mar 2015 | A1 |
Number | Date | Country |
---|---|---|
550575 | Mar 1986 | AU |
745271 | Mar 2002 | AU |
755496 | Dec 2002 | AU |
2005436 | Jun 1990 | CA |
26 40 413 | Mar 1978 | DE |
43 06 478 | Sep 1994 | DE |
29 504 378 | Sep 1995 | DE |
0100148 | Feb 1984 | EP |
0117632 | Sep 1984 | EP |
0161865 | Nov 1985 | EP |
0358302 | Mar 1990 | EP |
1018967 | Jul 2000 | EP |
692578 | Jun 1953 | GB |
2195255 | Apr 1988 | GB |
2 197 789 | Jun 1988 | GB |
2 220 357 | Jan 1990 | GB |
2 235 877 | Mar 1991 | GB |
2 329 127 | Mar 1999 | GB |
2 333 965 | Aug 1999 | GB |
4129536 | Aug 2008 | JP |
71559 | Apr 2002 | SG |
8002182 | Oct 1980 | WO |
8704626 | Aug 1987 | WO |
90010424 | Sep 1990 | WO |
93009727 | May 1993 | WO |
9420041 | Sep 1994 | WO |
9605873 | Feb 1996 | WO |
9718007 | May 1997 | WO |
9913793 | Mar 1999 | WO |
Entry |
---|
Louis C. Argenta, MD and Michael J. Morykwas, PhD; Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Clinical Experience; Annals of Plastic Surgery; vol. 38, No. 6, Jun. 1997; pp. 563-576. |
Susan Mendez-Eatmen, RN; “When wounds Won't Heal” RN Jan. 1998, vol. 61 (1); Medical Economics Company, Inc., Montvale, NJ, USA; pp. 20-24. |
James H. Blackburn II, MD et al.: Negative-Pressure Dressings as a Bolster for Skin Grafts; Annals of Plastic Surgery, vol. 40, No. 5, May 1998, pp. 453-457; Lippincott Williams & Wilkins, Inc., Philidelphia, PA, USA. |
John Masters; “Reliable, Inexpensive and Simple Suction Dressings”; Letter to the Editor, British Journal of Plastic Surgery, 1998, vol. 51 (3), p. 267; Elsevier Science/The British Association of Plastic Surgeons, UK. |
S.E. Greer, et al. “The Use of Subatmospheric Pressure Dressing Therapy to Close Lymphocutaneous Fistulas of the Groin” British Journal of Plastic Surgery (2000), 53, pp. 484-487. |
George V. Letsou, MD., et al; “Stimulation of Adenylate Cyclase Activity in Cultured Endothelial Cells Subjected to Cyclic Stretch”; Journal of Cardiovascular Surgery, 31, 1990, pp. 634-639. |
Orringer, Jay, et al; “Management of Wounds in Patients with Complex Enterocutaneous Fistulas”; Surgery, Gynecology & Obstetrics, Jul. 1987, vol. 165, pp. 79-80. |
International Search Report for PCT International Application PCT/GB95/01983; dated Nov. 23, 1995. |
PCT International Search Report for PCT International Application PCT/GB98/02713; dated Jan. 8, 1999. |
PCT Written Opinion; PCT International Application PCT/GB98/02713; dated Jun. 8, 1999. |
PCT International Examination and Search Report, PCT International Application PCT/GB96/02802; dated Jan. 15, 1998 & dated Apr. 29, 1997. |
PCT Written Opinion, PCT International Application PCT/GB96/02802; dated Sep. 3, 1997. |
Dattilo, Philip P., Jr., et al; “Medical Textiles: Application of an Absorbable Barbed Bi-directional Surgical Suture”; Journal of Textile and Apparel, Technology and Management, vol. 2, Issue 2, Spring 2002, pp. 1-5. |
Kostyuchenok, B.M., et al; “Vacuum Treatment in the Surgical Management of Purulent Wounds”; Vestnik Khirurgi, Sep. 1986, pp. 18-21 and 6 page English translation thereof. |
Davydov, Yu. A., et al; “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis”; Vestnik Khirurgi, May 14, 1986, pp. 66-70, and 9 page English translation thereof. |
Yusupov. Yu.N., et al; “Active Wound Drainage”, Vestnki Khirurgi, vol. 138, Issue 4, 1987, and 7 page English translation thereof. |
Davydov, Yu.A., et al; “Bacteriological and Cytological Assessment of Vacuum Therapy for Purulent Wounds”; Vestnik Khirugi, Oct. 1988, pp. 48-52, and 8 page English translation thereof. |
Davydov, Yu.A., et al; “Concepts for the Clinical-Biological Management of the Wound Process in the Treatment of Purulent Wounds by Means of Vacuum Therapy”; Vestnik Khirurgi, Jul. 7, 1980, pp. 132-136, and 8 page English translation thereof. |
Chariker, Mark E., M.D., et al; “Effective Management of incisional and cutaneous fistulae with closed suction wound drainage”; Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63. |
Egnell Minor, Instruction Book, First Edition, 300 7502, Feb. 1975, pp. 24. |
Egnell Minor: Addition to the Users Manual Concerning Overflow Protection—Concerns all Egnell Pumps, Feb. 3, 1983, pp. 2. |
Svedman, P.: “Irrigation Treatment of Leg Ulcers”, The Lancet, Sep. 3, 1983, pp. 532-534. |
Chinn, Steven D. et al.: “Closed Wound Suction Drainage”, The Journal of Foot Surgery, vol. 24, No. 1, 1985, pp. 76-81. |
Arnljots, Björn et al.: “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers”, Scand J. Plast Reconstr. Surg., No. 19, 1985, pp. 211-213. |
Svedman, P.: “A Dressing Allowing Continuous Treatment of a Biosurface”, IRCS Medical Science: Biomedical Technology, Clinical Medicine, Surgery and Transplantation, vol. 7, 1979, p. 221. |
Svedman, P. et al: “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous of Intermittent Irrigation”, Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133. |
N.A. Bagautdinov, “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues,” Current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye Volkov et al. (Chuvashia State University, Cheboksary, U.S.S.R. 1986); pp. 94-96 (copy and certified translation). |
K.F. Jeter, T.E. Tintle, and M. Chariker, “Managing Draining Wounds and Fistulae: New and Established Methods,” Chronic Wound Care, edited by D. Krasner (Health Management Publications, Inc., King of Prussia, PA 1990), pp. 240-246. |
G. {hacek over (Z)}ivadinovi?, V. ?uki?, {hacek over (Z)}. Maksimovi?, ?. Radak, and P. Pe{hacek over (s)}ka, “Vacuum Therapy in the Treatment of Peripheral Blood Vessels,” Timok Medical Journal 11 (1986), pp. 161-164 (copy and certified translation). |
F.E. Johnson, “An Improved Technique for Skin Graft Placement Using a Suction Drain,” Surgery, Gynecology, and Obstetrics 159 (1984), pp. 584-585. |
A.A. Safronov, Dissertation Abstract, Vacuum Therapy of Trophic Ulcers of the Lower Leg with Simultaneous Autoplasty of the Skin (Central Scientific Research Institute of Traumatology and Orthopedics, Moscow, U.S.S.R. 1967) (copy and certified translation). |
M. Schein, R. Saadia, J.R. Jamieson, and G.A.G. Decker, “The ‘Sandwich Technique’ in the Management of the Open Abdomen,” British Journal of Surgery 73 (1986), pp. 369-370. |
D.E. Tribble, An Improved Sump Drain-Irrigation Device of Simple Construction, Archives of Surgery 105 (1972) pp. 511-513. |
M.J. Morykwas, L.C. Argenta, E.I. Shelton-Brown, and W. McGuirt, “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation,” Annals of Plastic Surgery 38 (1997), pp. 553-562 (Morykwas I). |
C.E. Tennants, “The Use of Hypermia in the Postoperative Treatment of Lesions of the Extremities and Thorax,” Journal of the American Medical Association 64 (1915), pp. 1548-1549. |
Selections from W. Meyer and V. Schmieden, Bier's Hyperemic Treatment in Surgery, Medicine, and the Specialties: A Manual of Its Practical Application, (W.B. Saunders Co., Philadelphia, PA 1909), pp. 17-25, 44-64, 90-96, 167-170, and 210-211. |
V.A. Solovev et al., Guidelines, The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1987) (“Solovev Guidelines”). |
V.A. Kuznetsov & N.a. Bagautdinov, “Vacuum and Vacuum-Sorption Treatment of Open Septic Wounds,” in II All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Moscow, U.S.S.R. Oct. 28-29, 1986) pp. 91-92 (“Bagautdinov II”). |
V.A. Solovev, Dissertation Abstract, Treatment and Prevention of Suture Failures after Gastric Resection (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1988) (“Solovev Abstract”). |
V.A.C.® Therapy Clinical Guidelines: A Reference Source for Clinicians; Jul. 2007. |
Number | Date | Country | |
---|---|---|---|
20200237563 A1 | Jul 2020 | US |
Number | Date | Country | |
---|---|---|---|
61782713 | Mar 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15709154 | Sep 2017 | US |
Child | 16848533 | US | |
Parent | 14173947 | Feb 2014 | US |
Child | 15709154 | US |